 Home > Active Ingredient News > Antitumor Therapy > Front Oncol: Pyrotinib-based treatment of HER2+ advanced breast cancer patients: a multi-center retrospective study

Front Oncol: Pyrotinib-based treatment of HER2+ advanced breast cancer patients: a multi-center retrospective study

 Last Update: 2021-11-02
 Source: Internet
 Author: User

Tags

types anti inflammatory

hedge apple cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Breast cancer is one of the most common malignant tumors in the world
.

With the development of early detection and effective treatment, the mortality rate of breast cancer has declined

Breast cancer is one of the most common malignant tumors in the world

From 2019 Nian 2 Yue Zhi 2020 Nian 4 months, included a total of 141 Ming HER2 -positive breast cancer patients
.

The last follow-up was 2021 Nian 2 Yue

From 2019 Nian 2 Yue Zhi 2020 Nian 4 months, included a total of 141 Ming HER2 -positive breast cancer patients

Among the 141 patients, the median age was 52 years ( range 29-78 years )

104 patients (73.

As of 2021 years 2 months, the median follow-up of 11.

Overall PFS

Overall PFS Overall PFS

In patients with liver metastases, mPFS was 8.
7 months (95%CI, 6.
3-15.
4), while those without liver metastases were 12.
3 months (95%CI, 8.
8-23.
3) (HR=0.
72; 95%CI ,0.
44-1.
18;P=0.
174)
.

In patients with liver metastases, mPFS was 8.

With or without liver metastasis PFS

With or without liver metastasis PFS with or without liver metastasis PFS

The PFS of patients receiving pigtinib treatment> 2 line was shorter than that of patients ≤ 2 line treatment, which were 8.
4 months (95%CI, 5.
9-15.
4) and 15.
1 months (95%CI, 9.
3-22.
9) (HR= 0.
69; 95%CI, 0.
44-1.
10; P=0.
109)
.

The PFS of patients receiving pigtinib treatment> 2 line was shorter than that of patients ≤ 2 line treatment, which were 8.

Different treatment lines PFS

Different treatment lines PFSDifferent treatment lines PFS

The mPFS of patients who had previously received trastuzumab was 12.
2 months (95%CI, 7.
9-18.
8), while the mPFS of patients who had not received trastuzumab was 11.
8 months (95%CI, 6.
8-22.
9) (HR=1.
12; 95%CI, 0.
56-2.
25; P=0.
732)
.

The mPFS of patients who had previously received trastuzumab was 12.

PFS previously accepted or not

PFS previously accepted or not PFS previously accepted or not

In addition, the mPFS of patients with the combined capecitabine regimen and the non-combined capecitabine regimen were 15.
1 months (95%CI, 10.
0-18.
8) and 8.
4 months (95%CI, 6.
7-22.
9) (HR =1.
51;P=0.
072)
.

In addition, the mPFS of
patients with the combined capecitabine regimen and the non-combined capecitabine regimen were 15.

1 months (95%CI, 10.
0-18.
8) and 8.
4 months (95%CI, 6.
7-22.
9) (HR =1.
51;P=0.
072) .
In addition, combined with capecitabine regimen in patients with non-union capecitabine regimen of gemcitabine plus capecitabine treatment programs and non-capecitabine treatment options for patients in combination with capecitabine regimen with non-union capecitabine The mPFS of
patients with the tabine treatment regimen were 15.
1 months (95%CI, 10.
0-18.
8) and 8.
4 months (95%CI, 6.
7-22.
9) (HR=1.
51; P=0.
072) .
mPFS was 15.
1 months (95%CI, 10.
0-18.
8) and 8.
4 months (95%CI, 6.
7-22.
9) (HR=1.
51; P=0.
072)
.

With capecitabine or without PFS

Combined with capecitabine or without PFS combined with capecitabine or without PFS

In addition, in patients with brain metastases, the estimated PFS rate at 6 months is 70.
0%, and the PFS rate at 12 months is 60.
0% .
As of the data deadline, the median OS has not yet been reached .
In addition, among brain metastasis patients, it is estimated that among brain metastasis patients, it is estimated that the PFS rate at 6 months is 70.
0%, and the PFS rate at 12 months is 60.
0% .
As of the data deadline, the median OS has not yet been reached .
The 6-month PFS rate was 70.
0%, and the 12-month PFS rate was 60.
0%
.
As of the data deadline, the median OS has not yet been reached
.

PFS in patients with brain metastases

PFS in patients with brain metastases PFS in patients with brain metastases

The response of 70 patients with measurable lesions was evaluated
.
ORR was 38.
6%, and DCR was 85.
7%
.
One patient (1.
4%) had a complete remission, and 26 patients (37.
1%) had a partial remission
.
Thirty-three patients (47.
1%) were in stable condition, and 10 patients (14.
3%) were in progressive condition
.
The response of 70 patients with measurable lesions was evaluated
.
ORR was 38.
6%, and DCR was 85.
7%
.
One patient (1.
4%) had a complete remission, and 26 patients (37.
1%) had a partial remission
.
Thirty-three patients (47.
1%) were in stable condition, and 10 patients (14.
3%) were in progressive condition
.

No safety data was available for 14 patients, and the remaining 127 patients were included in the safety assessment
.
All levels and 3 Ji adverse events (AEs) , respectively 123 Li (96.
9%) and 14 Li (11.
0%) report
.
The most common AE was diarrhea (85.
0%) , but only 6 cases (4.
7%) reported grade 3 diarrhea
.
In addition, AEs ≥ 15% of patients include anemia (37.
0%) , leukopenia (24.
4%) , vomiting (24.
4%) , neutropenia (22.
0%), and hyperbilirubinemia (17.
3%)
.
There are no reports of treatment-related deaths
.
No safety data was available for 14 patients, and the remaining 127 patients were included in the safety assessment
.
All levels and 3 Ji adverse events (AEs) , respectively 123 Li (96.
9%) and 14 Li (11.
0%) report
.
The most common AE was diarrhea (85.
0%) , but only 6 cases (4.
7%) reported grade 3 diarrhea
.
In addition, AEs ≥ 15% of patients include anemia (37.
0%) , leukopenia (24.
4%) , vomiting (24.
4%) , neutropenia (22.
0%), and hyperbilirubinemia (17.
3%)
.
There are no reports of treatment-related deaths
.

Adverse reactions

Adverse reactions adverse reactions adverse reactions

In summary, studies have shown that pigtinib-based therapy has shown good efficacy and is well tolerated in HER2+ patients, especially ≤2 line therapy and combined capecitabine regimens
.

In summary, studies have shown that pigtinib-based therapy has shown good efficacy and is well tolerated
in HER2+ patients, especially ≤2 line therapy and combined capecitabine regimens .
In summary, studies have shown that pigotinib-based treatments have shown that piostinib-based treatments have shown good efficacy
in HER2+ patients.
And it is well tolerated, especially ≤2 line therapy and combined capecitabine regimen .
HER2+ patients showed good efficacy and well tolerated, especially ≤2 line therapy and combined capecitabine regimen
.

Original source:

Zhang L, Wu X, Zhou J, Zhu M, Yu H, Zhang Y, Zhao Y, Han Z, Guo Y, Guan X, Wang X, Xu H, Sun L, Zhang J, Zhuang M, Xie L, Yu S , Chen P, Feng J.
Pyrotinib in the Treatment of Women With HER2-Positive Advanced Breast Cancer: A Multicenter, Prospective, Real-World Study.
Front Oncol.
2021 Jul 16;11:699323.
doi: 10.
3389/fonc.
2021.
699323.
PMID: 34336688; PMCID: PMC8322968.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.